44 related articles for article (PubMed ID: 16086408)
1. High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.
Carr-Wilkinson J; O'Toole K; Wood KM; Challen CC; Baker AG; Board JR; Evans L; Cole M; Cheung NK; Boos J; Köhler G; Leuschner I; Pearson AD; Lunec J; Tweddle DA
Clin Cancer Res; 2010 Feb; 16(4):1108-18. PubMed ID: 20145180
[TBL] [Abstract][Full Text] [Related]
2. MDM2-Targeting Reassembly Peptide (TRAP) Nanoparticles for p53-Based Cancer Therapy.
Li F; Chen D; Sun Q; Wu J; Gan Y; Leong KW; Liang XJ
Adv Mater; 2023 Nov; 35(45):e2305164. PubMed ID: 37474204
[TBL] [Abstract][Full Text] [Related]
3. Integrins regulate the apoptotic response to DNA damage through modulation of p53.
Lewis JM; Truong TN; Schwartz MA
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3627-32. PubMed ID: 11904424
[TBL] [Abstract][Full Text] [Related]
4. Methylation Profiling of Specific Genes in Ependymomas.
Kanit N; Yalcin P; Erbayraktar S; Ozer E
Turk Patoloji Derg; 2022; 38(3):213-218. PubMed ID: 34854470
[TBL] [Abstract][Full Text] [Related]
5. Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma.
Michealraj KA; Kumar SA; Kim LJY; Cavalli FMG; Przelicki D; Wojcik JB; Delaidelli A; Bajic A; Saulnier O; MacLeod G; Vellanki RN; Vladoiu MC; Guilhamon P; Ong W; Lee JJY; Jiang Y; Holgado BL; Rasnitsyn A; Malik AA; Tsai R; Richman CM; Juraschka K; Haapasalo J; Wang EY; De Antonellis P; Suzuki H; Farooq H; Balin P; Kharas K; Van Ommeren R; Sirbu O; Rastan A; Krumholtz SL; Ly M; Ahmadi M; Deblois G; Srikanthan D; Luu B; Loukides J; Wu X; Garzia L; Ramaswamy V; Kanshin E; Sánchez-Osuna M; El-Hamamy I; Coutinho FJ; Prinos P; Singh S; Donovan LK; Daniels C; Schramek D; Tyers M; Weiss S; Stein LD; Lupien M; Wouters BG; Garcia BA; Arrowsmith CH; Sorensen PH; Angers S; Jabado N; Dirks PB; Mack SC; Agnihotri S; Rich JN; Taylor MD
Cell; 2020 Jun; 181(6):1329-1345.e24. PubMed ID: 32445698
[TBL] [Abstract][Full Text] [Related]
6. An in vivo screen identifies ependymoma oncogenes and tumor-suppressor genes.
Mohankumar KM; Currle DS; White E; Boulos N; Dapper J; Eden C; Nimmervoll B; Thiruvenkatam R; Connelly M; Kranenburg TA; Neale G; Olsen S; Wang YD; Finkelstein D; Wright K; Gupta K; Ellison DW; Thomas AO; Gilbertson RJ
Nat Genet; 2015 Aug; 47(8):878-87. PubMed ID: 26075792
[TBL] [Abstract][Full Text] [Related]
7. Biological Mechanisms to Reduce Radioresistance and Increase the Efficacy of Radiotherapy: State of the Art.
Busato F; Khouzai BE; Mognato M
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142122
[TBL] [Abstract][Full Text] [Related]
8. A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-κB.
Ozawa T; Arora S; Szulzewsky F; Juric-Sekhar G; Miyajima Y; Bolouri H; Yasui Y; Barber J; Kupp R; Dalton J; Jones TS; Nakada M; Kumabe T; Ellison DW; Gilbertson RJ; Holland EC
Cell Rep; 2018 Jun; 23(13):3787-3797. PubMed ID: 29949764
[TBL] [Abstract][Full Text] [Related]
9. New
Plessier A; Le Dret L; Varlet P; Beccaria K; Lacombe J; Mériaux S; Geffroy F; Fiette L; Flamant P; Chrétien F; Blauwblomme T; Puget S; Grill J; Debily MA; Castel D
Oncotarget; 2017 Aug; 8(32):52543-52559. PubMed ID: 28881750
[TBL] [Abstract][Full Text] [Related]
10. Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma.
Tzaridis T; Milde T; Pajtler KW; Bender S; Jones DT; Müller S; Wittmann A; Schlotter M; Kulozik AE; Lichter P; Peter Collins V; Witt O; Kool M; Korshunov A; Pfister SM; Witt H
Oncotarget; 2016 Sep; 7(38):61860-61873. PubMed ID: 27556362
[TBL] [Abstract][Full Text] [Related]
11. Paired box 5 is a frequently methylated lung cancer tumour suppressor gene interfering β-catenin signalling and GADD45G expression.
Zhao L; Li S; Gan L; Li C; Qiu Z; Feng Y; Li J; Li L; Li C; Peng W; Xu C; Wang Z; Hui T; Ren G; Tao Q; Xiang T
J Cell Mol Med; 2016 May; 20(5):842-54. PubMed ID: 26843424
[TBL] [Abstract][Full Text] [Related]
12. Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups.
Pajtler KW; Witt H; Sill M; Jones DT; Hovestadt V; Kratochwil F; Wani K; Tatevossian R; Punchihewa C; Johann P; Reimand J; Warnatz HJ; Ryzhova M; Mack S; Ramaswamy V; Capper D; Schweizer L; Sieber L; Wittmann A; Huang Z; van Sluis P; Volckmann R; Koster J; Versteeg R; Fults D; Toledano H; Avigad S; Hoffman LM; Donson AM; Foreman N; Hewer E; Zitterbart K; Gilbert M; Armstrong TS; Gupta N; Allen JC; Karajannis MA; Zagzag D; Hasselblatt M; Kulozik AE; Witt O; Collins VP; von Hoff K; Rutkowski S; Pietsch T; Bader G; Yaspo ML; von Deimling A; Lichter P; Taylor MD; Gilbertson R; Ellison DW; Aldape K; Korshunov A; Kool M; Pfister SM
Cancer Cell; 2015 May; 27(5):728-43. PubMed ID: 25965575
[TBL] [Abstract][Full Text] [Related]
13. Chromosomal anomalies and prognostic markers for intracranial and spinal ependymomas.
Yang I; Nagasawa DT; Kim W; Spasic M; Trang A; Lu DC; Martin NA
J Clin Neurosci; 2012 Jun; 19(6):779-85. PubMed ID: 22516549
[TBL] [Abstract][Full Text] [Related]
14. A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat.
Milde T; Kleber S; Korshunov A; Witt H; Hielscher T; Koch P; Kopp HG; Jugold M; Deubzer HE; Oehme I; Lodrini M; Gröne HJ; Benner A; Brüstle O; Gilbertson RJ; von Deimling A; Kulozik AE; Pfister SM; Martin-Villalba A; Witt O
Acta Neuropathol; 2011 Nov; 122(5):637-50. PubMed ID: 21863243
[TBL] [Abstract][Full Text] [Related]
15. UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53.
Wu H; Pomeroy SL; Ferreira M; Teider N; Mariani J; Nakayama KI; Hatakeyama S; Tron VA; Saltibus LF; Spyracopoulos L; Leng RP
Nat Med; 2011 Mar; 17(3):347-55. PubMed ID: 21317885
[TBL] [Abstract][Full Text] [Related]
16. Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma.
Tabori U; Wong V; Ma J; Shago M; Alon N; Rutka J; Bouffet E; Bartels U; Malkin D; Hawkins C
Br J Cancer; 2008 Oct; 99(7):1129-35. PubMed ID: 18797459
[TBL] [Abstract][Full Text] [Related]
17. Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective.
de Bont JM; Packer RJ; Michiels EM; den Boer ML; Pieters R
Neuro Oncol; 2008 Dec; 10(6):1040-60. PubMed ID: 18676356
[TBL] [Abstract][Full Text] [Related]
18. p53 Pathway dysfunction in primary childhood ependymomas.
Gaspar N; Grill J; Geoerger B; Lellouch-Tubiana A; Michalowski MB; Vassal G
Pediatr Blood Cancer; 2006 May; 46(5):604-13. PubMed ID: 16086408
[TBL] [Abstract][Full Text] [Related]
19. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma.
Mori S; Ito G; Usami N; Yoshioka H; Ueda Y; Kodama Y; Takahashi M; Fong KM; Shimokata K; Sekido Y
Cancer; 2004 Apr; 100(8):1673-82. PubMed ID: 15073856
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]